Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 5 Date: 26 Jul 2024
Reviewer's report:
1. Although the number of patients is small, the authors do indicate this is the first ICI/chemo
combined study for induction in ESCC - unique.
2. The study is straightforward and simple. However, they do not include survival or disease free
survival data, This would be useful for the manuscript, particularly as this is a Phase II study.
3. Although the authors state their reasoning, it would still be useful to include RECIST
calculations as it remains a standard.
4. Authors  should discuss latest findings from ASCO with FLOT chemotherapy and how it
compares to their regimen.
5. Please indicate funding source and any trial registration site.
Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 5 Date: 26 Jul 2024
Reviewer's report:
1. Although the number of patients is small, the authors do indicate this is the first ICI/chemo
combined study for induction in ESCC - unique.
2. The study is straightforward and simple. However, they do not include survival or disease free
survival data, This would be useful for the manuscript, particularly as this is a Phase II study.
3. Although the authors state their reasoning, it would still be useful to include RECIST
calculations as it remains a standard.
4. Authors  should discuss latest findings from ASCO with FLOT chemotherapy and how it
compares to their regimen.
5. Please indicate funding source and any trial registration site.
Please review this paper.
user
Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 5 Date: 26 Jul 2024
Reviewer's report:
1. Although the number of patients is small, the authors do indicate this is the first ICI/chemo
combined study for induction in ESCC - unique.
2. The study is straightforward and simple. However, they do not include survival or disease free
survival data, This would be useful for the manuscript, particularly as this is a Phase II study.
3. Although the authors state their reasoning, it would still be useful to include RECIST
calculations as it remains a standard.
4. Authors  should discuss latest findings from ASCO with FLOT chemotherapy and how it
compares to their regimen.
5. Please indicate funding source and any trial registration site.
assistant